CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $113,716
- in 1 filing, $114K under 10b5-1 plans
Net −$113,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-09 | Ondrey Aaron Chief Financial Officer | Grant or award · Stock Option (Right to buy) | +270,000 | $9.55 | $2.6M | 0 |
| 2026-10-29 | Podlesak Dennis Director | Option exercise 10b5-1 | +8,000 | $11.81 | $94K | 247,763 |
| 2026-10-29 | Podlesak Dennis Director | Sale 10b5-1 | −8,000 | $14.21 | $114K | 239,763 |
| 2026-10-29 | Podlesak Dennis Director | Option exercise · Stock Options (Right to buy) 10b5-1 | −8,000 | 0 | ||
| 2026-07-08 | Metzger Michael A Chief Executive Officer | Option exercise 10b5-1 | +32,375 | $6.38 | $207K | 517,218 |
| 2026-07-08 | Metzger Michael A Chief Executive Officer | Sale 10b5-1 | −32,375 | $24.24 | $785K | 484,843 |
| 2026-07-08 | Metzger Michael A Chief Executive Officer | Option exercise · Stock Option (Right to buy) 10b5-1 | +32,375 | 0 | ||
| 2026-06-12 | Botwood Nicholas A.J. Head of R&D, CMO | Option exercise 10b5-1 | +31,235 | $13.82 | $432K | 92,120 |
| 2026-06-12 | Botwood Nicholas A.J. Head of R&D, CMO | Sale 10b5-1 | −31,235 | $18.14 | $567K | 60,885 |
| 2026-06-12 | Botwood Nicholas A.J. Head of R&D, CMO | Option exercise · Stock options (Right to buy) 10b5-1 | +31,235 | 0 | ||
| 2026-06-11 | Botwood Nicholas A.J. Head of R&D, CMO | Option exercise 10b5-1 | +22,515 | $13.82 | $311K | 95,165 |
| 2026-06-11 | Botwood Nicholas A.J. Head of R&D, CMO | Sale 10b5-1 | −34,280 | $18.00 | $617K | 60,885 |
| 2026-06-11 | Botwood Nicholas A.J. Head of R&D, CMO | Option exercise · Stock options (Right to buy) 10b5-1 | +22,515 | 0 | ||
| 2026-06-01 | Goldan Keith A. Chief Financial Officer | Sale | −1,177 | $18.99 | $22K | 139,252 |
| 2026-06-01 | Metzger Michael A Chief Executive Officer | Sale | −6,847 | $18.99 | $130K | 484,843 |
| 2026-02-09 | Metzger Michael A Chief Executive Officer | Sale | −17,159 | $21.03 | $361K | 491,690 |
| 2026-02-09 | Goldan Keith A. Chief Financial Officer | Sale | −3,410 | $21.03 | $72K | 140,429 |
| 2026-02-06 | Metzger Michael A Chief Executive Officer | Sale | −7,412 | $20.62 | $153K | 508,849 |
| 2026-02-06 | Goldan Keith A. Chief Financial Officer | Sale | −2,082 | $20.62 | $43K | 143,839 |
| 2026-02-04 | Metzger Michael A Chief Executive Officer | Grant or award | +73,000 | 371,661 |
Page 1 of 15 · 290 trades